MA54958A - Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée - Google Patents

Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée

Info

Publication number
MA54958A
MA54958A MA054958A MA54958A MA54958A MA 54958 A MA54958 A MA 54958A MA 054958 A MA054958 A MA 054958A MA 54958 A MA54958 A MA 54958A MA 54958 A MA54958 A MA 54958A
Authority
MA
Morocco
Prior art keywords
modulation
closed
protein activity
rep protein
end dna
Prior art date
Application number
MA054958A
Other languages
English (en)
Inventor
Robert Michael Kotin
Ara Karl Malakian
Anna Ucher
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MA54958A publication Critical patent/MA54958A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054958A 2019-02-15 2020-02-14 Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée MA54958A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962806076P 2019-02-15 2019-02-15

Publications (1)

Publication Number Publication Date
MA54958A true MA54958A (fr) 2021-12-22

Family

ID=72045641

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054958A MA54958A (fr) 2019-02-15 2020-02-14 Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée

Country Status (11)

Country Link
US (1) US20220127625A1 (fr)
EP (1) EP3924491A4 (fr)
JP (1) JP2022520803A (fr)
KR (1) KR20210127935A (fr)
CN (1) CN113454232A (fr)
AU (1) AU2020221312A1 (fr)
CA (1) CA3129321A1 (fr)
IL (1) IL285415A (fr)
MA (1) MA54958A (fr)
SG (1) SG11202106491VA (fr)
WO (1) WO2020168222A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020251954A1 (fr) * 2019-06-10 2020-12-17 Homology Medicines, Inc. Compositions de virus adéno-associés pour transfert de gène arsa et leurs procédés d'utilisation
CN116234917A (zh) 2020-07-27 2023-06-06 安杰瑞姆生物科学公司 Dna分子组合物及其制备方法和使用方法
EP4267197A1 (fr) * 2020-12-23 2023-11-01 Vivet Therapeutics Promoteurs inductibles par l'acide biliaire minimal pour thérapie génique
WO2022197854A1 (fr) * 2021-03-16 2022-09-22 Wisconsin Alumni Research Foundation Thérapie génique de l'insuline pour traiter le diabète
KR20240049821A (ko) * 2021-08-23 2024-04-17 바이오버라티브 테라퓨틱스 인크. 바큘로바이러스 발현 시스템
CN114703203A (zh) * 2022-02-11 2022-07-05 上海渤因生物科技有限公司 杆状病毒载体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506369B (zh) * 2006-06-21 2014-02-12 尤尼克尔生物制药股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav-rep78翻译起始密码子的载体
EP2500434A1 (fr) * 2011-03-12 2012-09-19 Association Institut de Myologie Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique
MX2016011585A (es) * 2014-03-10 2016-11-29 Uniqure Ip Bv Vectores aav mejorados adicionales producidos en celulas de insecto.
SG10201913688TA (en) * 2016-03-03 2020-03-30 Univ Massachusetts Closed-ended linear duplex dna for non-viral gene transfer
US20210163986A1 (en) * 2017-08-09 2021-06-03 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof

Also Published As

Publication number Publication date
EP3924491A4 (fr) 2022-12-14
CA3129321A1 (fr) 2020-08-20
CN113454232A (zh) 2021-09-28
SG11202106491VA (en) 2021-07-29
WO2020168222A1 (fr) 2020-08-20
IL285415A (en) 2021-09-30
AU2020221312A1 (en) 2021-10-07
US20220127625A1 (en) 2022-04-28
EP3924491A1 (fr) 2021-12-22
KR20210127935A (ko) 2021-10-25
JP2022520803A (ja) 2022-04-01

Similar Documents

Publication Publication Date Title
MA54958A (fr) Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée
MA50942A (fr) Protéines de liaison à l'adn modifiées
MA51842A (fr) Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion
MA51644A (fr) Méthodes d'évaluation de la capacité de transduction de vecteurs viraux
MA52570A (fr) Formulations contenant des protéines de fusion du récepteur vegf à haute concentration
IS8282A (is) Kortlagning genamengja starfrænna DNA þátta og frumuprótína
CY2016039I2 (el) Χιμαιρικες πρωτεϊνες παραγοντα πηξης για την αγωγη αιμοστατικων ασθενειων
CY1118576T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23
BRPI0512286B8 (pt) proteínas quiméricas inibidoras da angiogênese e o uso
EA200971077A1 (ru) Гетероциклические модуляторы киназы
DK1799235T3 (da) Sammensætninger af fosterhudcelleprotein til behandling af hudtilstande, -lidelser eller -sygdomme og fremgangsmåder til fremstilling og anvendelse deraf
ATE472317T1 (de) Kosmetische verwendung von molkeproteinmizellen
DE602006021628D1 (de) Verbesserte synthese und zubereitungen von duloxetinsalzen
DE602005001929D1 (de) Sulfonamidderivate zur behandlung von krankheiten
DK3906066T3 (da) Geneterapikonstruktioner til behandling af wilsons sygdom
MA50534A (fr) Variant d'anticorps et isoforme à activité biologique réduite
DK3740222T3 (da) Modificeret RAAV-capsidprotein til genterapi
EA201492048A1 (ru) Полипептиды, связывающиеся с хемокиновым рецептором
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
MA54188A (fr) Adn à extrémité fermée modifié (cedna) comprenant des répétitions terminales inversées modifiées symétriques
MA51619A (fr) Inhibiteurs de la protéine kinase dépendante de l'adn
DE602006000511D1 (de) Dermatologische verwendung von proteinen aus milch
FR2835829B1 (fr) Nouveau procede de preparation de biopuces a adn ou a proteines et leurs applications
MA53548A (fr) Formulations antiparasitaires de goût agréable
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf